Jan Lubiński (Polish oncologist, pathologist and hereditary cancer researcher)

author (P50)

Q36016386	11q13 is a susceptibility locus for hormone receptor positive breast cancer
Q36108172	A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
Q57666866	A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8
Q34975938	A case of carotid body paraganglioma and haemangioblastoma of the spinal cord in a patient with the N131K missense mutation in the VHL gene
Q93025301	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Q25257499	A common missense variant in BRCA2 predisposes to early onset breast cancer
Q43566825	A common nonsense mutation of the BLM gene and prostate cancer risk and survival
Q35447197	A common variant of CDKN2A (p16) predisposes to breast cancer
Q89999716	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy
Q80081672	A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
Q21090783	A genome-wide analysis of populations from European Russia reveals a new pole of genetic diversity in northern Europe
Q54246649	A genome-wide association study for extremely high intelligence.
Q33747778	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
Q35747147	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23
Q29417084	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
Q33855653	A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium
Q61945696	A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer
Q34548008	A high proportion of founder BRCA1 mutations in Polish breast cancer families
Q36927109	A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer
Q37619303	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
Q35089479	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
Q34630272	A low selenium level is associated with lung and laryngeal cancers
Q36477652	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease
Q92711687	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Q59237589	A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer
Q36152991	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers
Q37089839	A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome
Q47755538	A novel founder CHEK2 mutation is associated with increased prostate cancer risk
Q36959139	A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
Q37719595	A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers
Q35444317	A protein truncating BRCA1 allele with a low penetrance of breast cancer
Q36770256	A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer
Q34756970	A sex-specific association between a 15q25 variant and upper aerodigestive tract cancers
Q80243539	A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population
Q79652344	A survey of preventive measures among BRCA1 mutation carriers from Poland
Q57305942	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
Q29417157	A variant in FTO shows association with melanoma risk not due to BMI
Q36739719	AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening
Q64007423	ARLTS1 Trp149Stop Mutation and the Risk of Ovarian Cancer
Q37417780	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
Q36091711	Abdominal integument atrophy after operative procedures
Q71579903	Abnormalities of chromosome 5q correlate with morphologic features of better prognosis in clear cell renal carcinomas
Q41022077	Absence or reduction of Fhit expression in most clear cell renal carcinomas.
Q60684176	Abstract LB-159: Methylation of BRCA1 gene in blood is not inherited via maternal germ line and may predispose to triple-negative or medullary breast cancer
Q87587823	Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
Q41864610	Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease
Q38406780	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study
Q52647897	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
Q79176607	Age at diagnosis of cancer as predictor of mutation occurrence in families suspected of HNPCC
Q61946740	Age at diagnosis to discriminate those patients for whom constitutional DNA sequencing is appropriate in sporadic unilateral retinoblastoma
Q57266698	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q88723598	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q59238426	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q46850294	Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53.
Q39437211	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
Q88791860	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation
Q90905912	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers
Q37129674	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers
Q92607891	Allelic modification of breast cancer risk in women with an NBN mutation
Q122923901	An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer
Q122920530	An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer
Q36882665	An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers
Q36594121	An inherited NBN mutation is associated with poor prognosis prostate cancer
Q36073563	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression
Q33901361	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
Q35618307	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers
Q33473894	Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma
Q36831854	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome
Q57266543	Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers
Q80753455	Antigens HLA-G, sHLA- G and sHLA- class I in reproductive failure
Q37056869	Are two-centimeter breast cancers large or small?
Q55340907	Arsenic (As) and breast cancer risk.
Q57567527	Aryl hydrocarbon receptor interacting protein(AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas
Q35242849	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers
Q30276986	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes
Q37684409	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Q57305944	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Q45979098	Association analysis identifies 65 new breast cancer risk loci.
Q54628253	Association between early-onset breast and laryngeal cancers.
Q61946716	Association of MMP8 gene variation with an increased risk of malignant melanoma
Q36072765	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
Q37684672	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Q36586393	Association of common WRAP 53 variant with ovarian cancer risk in the Polish population
Q37268494	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
Q114182713	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
Q56337548	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Q113241843	Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
Q35957703	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
Q39423088	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Q90414420	Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population
Q35022847	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
Q35523236	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
Q35532898	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium
Q57056093	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Q40521165	Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland
Q53515244	Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer.
Q63966080	Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Q64118820	Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Q24531993	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
Q53567982	BARD1 and breast cancer in Poland.
Q92377257	BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation
Q54859162	BRCA1 founder mutations and ovarian cancer in Belarus.
Q34185187	BRCA1 founder mutations compared to ovarian cancer in Belarus
Q36466697	BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Q54409850	BRCA1 mutations and colorectal cancer in Poland.
Q43632939	BRCA1 mutations and prostate cancer in Poland
Q93009431	BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer
Q37327095	BRCA1 testing
Q46054315	BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms
Q44949616	BRCA1-positive breast cancers in young women from Poland.
Q42481914	BRCA1-related gene signature in breast cancer: the role of ER status and molecular type
Q57031136	BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population
Q48906011	BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Q38914005	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer
Q37002955	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Q36646182	BRCA2 gene mutations in families with aggregations of breast and stomach cancers
Q40592257	Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Q93553514	Blood and serum samples collection and storage for further selenium measurements
Q92201901	Blood arsenic levels and the risk of familial breast cancer in Poland
Q103045173	Blood cadmium levels as a marker for early lung cancer detection
Q46115524	Body mass index and breast cancer survival: a Mendelian randomization analysis
Q100457582	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk
Q43073201	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
Q43535015	Breast cancer genetics: 20 years later
Q81892020	Breast cancer predisposing alleles in Poland
Q53265333	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Q73400704	Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland
Q35940158	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Q57666904	Breast cancer susceptibility genes
Q53287209	Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Q24598482	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q100430759	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
Q34306552	CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland
Q56436889	CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population
Q43806333	CDKN2A common variant and multi-organ cancer risk--a population-based study
Q45261315	CDKN2A common variants and their association with melanoma risk: a population-based study.
Q54574835	CDKN2A-positive breast cancers in young women from Poland.
Q112162492	CHAPTER 22. Selenium and Cancer
Q57666885	CHEK2 germline mutations correlate with recurrence rate in patients with superficial bladder cancer
Q34551970	CHEK2 is a multiorgan cancer susceptibility gene
Q53362846	CHEK2 mutations and HNPCC-related colorectal cancer.
Q52976068	CHEK2 mutations and the risk of papillary thyroid cancer.
Q46250042	CHEK2 mutations as markers for high risk of breast cancer
Q60661770	CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors
Q80128998	CHEK2-positive breast cancers in young Polish women
Q57666910	CYP1B1 and predisposition to breast cancer in Poland
Q92118186	Can Serum Iron Concentrations in Early Healthy Pregnancy Be Risk Marker of Pregnancy-Induced Hypertension?
Q46658012	Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?
Q34693954	Can selenium levels act as a marker of colorectal cancer risk?
Q28304288	Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene
Q100382837	Cancer Predisposition Genes in Cancer-Free Families
Q36930042	Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status
Q37222641	Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
Q47636266	Cancer variation associated with the position of the mutation in the BRCA2 gene
Q34963894	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q42836975	Case report of a woman with monoclonal gammapathy and papillary thyroid carcinoma, diagnosed because of detection of CHEK2 (I157T) mutation in genetic examinations.
Q24813705	Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q77447971	Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation
Q43417392	Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg).
Q37249356	Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation
Q59270806	Chromosome 8q23.3, 10p14 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome – a combined analysis of the Australian, Dutch and Polish Lynch syndrome cohorts
Q40471790	Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome.
Q35782435	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer
Q59288510	Cisplatin in breast cancer treatment in BRCA1 carriers
Q62588935	Clinical and epidemiological features of familial laryngeal cancer in Poland
Q53088764	Clinical characteristics of breast cancer in patients with an NBS1 mutation.
Q73039579	Clinical characteristics of hereditary ovarian cancer (HOC) in Poland
Q84216893	Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers
Q61946717	Clinical characteristics of tumors derived from colorectal cancer patients who harbor the tumor necrosis factor alpha-1031T/T and NOD2 3020insC polymorphism.
Q79843110	Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2
Q37363736	Clinical genetic services for familial breast cancer in Poland
Q41748948	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis
Q57591060	Coffee consumption and breast cancer risk amongBRCA1 andBRCA2 mutation carriers
Q51531738	Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome.
Q61946713	Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers
Q41869270	Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients
Q47110534	Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients
Q35668946	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Q36490507	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).
Q36839777	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
Q34126314	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer
Q34394665	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction
Q34949394	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers
Q35794653	Common germline polymorphisms associated with breast cancer-specific survival
Q34379032	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium
Q41025905	Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas
Q36393232	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
Q29417145	Common variants at 19p13 are associated with susceptibility to ovarian cancer
Q35870067	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q36255665	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer
Q34585088	Common variants of DNA repair genes and malignant melanoma
Q37638886	Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk
Q35188902	Common variants of xeroderma pigmentosum genes and prostate cancer risk
Q61946733	Comparison of Alu-PCR, microsatellite instability, and immunohistochemical analyses in finding features characteristic for hereditary nonpolyposis colorectal cancer
Q38475708	Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events
Q34367165	Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization
Q34181322	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer
Q34342248	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk
Q43825646	Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers
Q46899355	Constitutional methylation of cancer-related and selenoprotein coding genes in breast carcinoma in Polish population
Q99719061	Constitutional variants in POT1, TERF2IP, and ACD genes in patients with melanoma in the Polish population
Q28266112	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population
Q45906878	Copper as diagnostic marker of cancers.
Q122925877	Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment
Q45866501	Correction: A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium.
Q93590170	Correction: A Low Selenium Level Is Associated with Lung and Laryngeal Cancers
Q55455505	Correction: Genetic Structure of Europeans: A View from the North–East.
Q55039316	Correction: Serum selenium levels and the risk of progression of laryngeal cancer.
Q57565042	Corrigendum re “Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma” [Eur Urol 2017;72:747–54]
Q89080190	Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility
Q41839357	Coverage of the genetic background of breast cancer in the polish population
Q35697872	Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia
Q60609700	Cumulative effects of genetic markers and the detection of advanced colorectal neoplasias by population screening
Q55396825	Cumulative small effect genetic markers and the detection of advanced colorectal neoplasias by population screening.
Q81612263	Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas
Q21144874	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers
Q61946715	DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome
Q37327200	DNA testing for variants conferring low or moderate increase in the risk of cancer
Q80602772	DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland
Q48353045	Detection of germline mutations in the BRCA1 gene by RNA-based sequencing
Q40973687	Detection of specific genetic alterations in cancer cells.
Q96590073	Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE)
Q36144591	Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations
Q42490495	Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer
Q79811213	Direct-to-patient BRCA1 testing: the Twoj Styl experience
Q46205547	Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
Q40821559	Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Q90904798	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
Q41221895	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Q43924266	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
Q46168959	Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations
Q37681297	Dupuytren's disease and the risk of malignant neoplasms
Q34039438	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Q80514712	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland
Q53316752	Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Q34901055	Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome
Q47614988	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers
Q43807157	Electro-oculogram in patients with neurofibromatosis type 1.
Q44550725	Electro-oculographic and electroretinographic studies in HNPCC gene mutation carriers
Q44414782	Electroretinographic Changes in Eyes of Patients with BRCA1 Gene Mutation
Q44108789	Electroretinographic changes in the inner retinal layers of the retained eyes of patients with sporadic unilateral retinoblastoma
Q45923424	Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
Q54487187	Endolymphatic sac tumours and von Hippel-Lindau disease - case report, molecular analysis and histopathological characterization.
Q38889842	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Q38720533	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci
Q71273195	Environmental factors may regulate BCL2 associated lymphomagenesis: a very low incidence of BCL2-MBR translocation in Poland
Q24633316	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
Q79986282	Epistatic relationship between the cancer susceptibility genes CHEK2 and p27
Q36487146	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk
Q57319395	Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer
Q57271291	Erratum: Corrigendum: Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
Q61946721	Erratum: Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Q33932856	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium
Q46236360	Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention
Q36966218	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study
Q33614244	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
Q35064451	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Q37342144	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
Q38845261	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk
Q33761201	Exploring the link between germline and somatic genetic alterations in breast carcinogenesis
Q37594336	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
Q35690548	Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Q37350151	Familial adenomatous polyposis of the colon
Q57666897	Familial association of laryngeal, lung, stomach and early-onset breast cancer
Q57266614	Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations
Q46738228	Fast diagnostic test for the identification of an increased genetic predisposition to colon cancer (exemplified on a DNA test for recurrent mutations of the gene MMR).
Q43933998	Fhit protein expression in endometrial cancers: no correlation with histological grade.
Q43840975	Fhit protein expression in hereditary and sporadic colorectal cancers
Q35083710	Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions
Q37236216	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).
Q36111237	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
Q36087170	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Q36856343	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression
Q55380382	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.
Q35524465	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.
Q61230414	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes
Q92480972	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Q55311842	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
Q39844032	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
Q36248936	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk
Q34903062	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Q37367871	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
Q92120641	First Trimester Microelements and their Relationships with Pregnancy Outcomes and Complications
Q90774461	First Trimester Serum Copper or Zinc Levels, and Risk of Pregnancy-Induced Hypertension
Q54201748	First recurrent large genomic rearrangement in the BRCA1 gene found in Poland.
Q55638405	Folic acid and breast cancer risk.
Q46250083	Folic acid and cancer risk in BRCA1 carriers.
Q64895719	Founder Mutations for Early Onset Melanoma as Revealed by Whole Exome Sequencing Suggests That This is Not Associated with the Increasing Incidence of Melanoma in Poland.
Q24540270	Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
Q77642899	Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families
Q42539153	Founder mutations of BRCA1 and BRCA2 in North American families of Polish origin that are affected with breast cancer
Q61946735	Frequency and nature of germline Rb-1 gene mutations in a series of patients with sporadic unilateral retinoblastoma
Q61945791	Frequency and nature of hMSH6 germline mutations in Polish patients with colorectal, endometrial and ovarian cancers
Q50320232	Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.
Q113241840	Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
Q61946718	Frequency of mutations related to hereditary haemochromatosis in northwestern Poland
Q114182808	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
Q36124728	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
Q33706508	Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer
Q36742577	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
Q36956156	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
Q36108160	Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report
Q55340947	Gene expression signature of hereditary breast cancer.
Q68255553	Gene rearrangements detected by nonradioactive digoxigenin-labeled DNA probes
Q61946724	Genetic Polymorphisms in Xenobiotic Clearance Genes and Their Influence on Disease Expression in Hereditary Nonpolyposis Colorectal Cancer Patients
Q39200248	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma
Q34318389	Genetic characterization of northeastern Italian population isolates in the context of broader European genetic diversity
Q57666860	Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology
Q37358018	Genetic epidemiology studies in hereditary non-polyposis colorectal cancer
Q54494898	Genetic heterogeneity of 8q24 region in susceptibility to cancer.
Q58798369	Genetic polymorphisms may influence the vertical growth rate of melanoma
Q35925620	Genetic predisposition to ductal carcinoma in situ of the breast
Q35151684	Genetic predisposition to in situ and invasive lobular carcinoma of the breast
Q21143785	Genetic structure of Europeans: a view from the North-East
Q22330767	Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders
Q35022825	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers
Q35179897	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
Q34955369	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk
Q34378972	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
Q36422109	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium
Q30000080	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
Q28388497	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types
Q36218993	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Q36842233	Genome-wide association analysis identifies three new breast cancer susceptibility loci
Q35996692	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Q63681757	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Q93270780	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
Q24622610	Genome-wide association studies identify four ER negative-specific breast cancer risk loci
Q95329367	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Q33804470	Genome-wide association study identifies multiple risk loci for renal cell carcinoma
Q37341178	Genome-wide association study identifies three loci associated with melanoma risk
Q29416994	Genome-wide association study identifies three new melanoma susceptibility loci
Q27008356	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
Q64040390	Genome-wide association study of germline variants and breast cancer-specific mortality
Q38970751	Genome-wide association study of prostate cancer-specific survival
Q28943264	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3
Q33778612	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
Q36019187	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma
Q57697186	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes
Q117813333	Genomic dissection of bipolar disorder and schizophrenia including 28 subphenotypes
Q68020074	Genotypic analysis of DNA isolated from fine needle aspiration biopsies
Q38397639	Genotyping by induced Förster Resonance Energy Transfer(iFRET) mechanism and simultaneous mutation scanning
Q61946729	Germline 657del5 mutation in the NBS1 gene in breast cancer patients
Q54763302	Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin.
Q113241839	Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
Q34572576	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Q113241854	Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population
Q96432094	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk
Q43075069	Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States
Q61945792	Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study)
Q41010238	Germline RECQL mutations are associated with breast cancer susceptibility
Q37152623	Germline deletions in the EPCAM gene as a cause of Lynch syndrome - literature review
Q34517815	Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma
Q47661461	Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer
Q35440133	Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene
Q57666880	Germline mutations in theCHEK2 kinase gene are associated with an increased risk of bladder cancer
Q114182677	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis
Q54430705	HFE gene mutations in patients with alcoholic liver disease. A prospective study from northwestern Poland.
Q51752833	HLA-G polymorphism and in vitro fertilization failure in a Polish population.
Q81522589	HLA-G polymorphism in a Polish population and reproductive failure
Q93493049	HNPCC (Lynch Syndrome): Differential Diagnosis, Molecular Genetics and Management - a Review
Q55207786	HOXB13 mutations and prostate cancer in Poland.
Q51765453	Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age.
Q84211456	Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals
Q35382206	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
Q54473072	Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.
Q57471595	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study
Q36276540	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
Q46413116	Hereditary Cancer in Clinical Practice transfers to BioMed Central.
Q84632533	Hereditary breast and ovarian cancer
Q93913357	Hereditary breast cancer
Q43683502	Hereditary ovarian cancer in Poland.
Q34746938	High Resolution Melting analysis as a rapid and efficient method of screening for small mutations in the STK11 gene in patients with Peutz-Jeghers syndrome.
Q81425179	High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families
Q38806848	Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial
Q30580888	Hippel-Lindau disease
Q88516911	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers
Q93492613	Hormone Replacement Therapy Appears to Be Safe After Prophylactic Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers. Reaction to the 'Letter to readers' in Hereditary Cancer in Clinical Practice, 2005, 3 (2)
Q47635634	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study
Q53354746	Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Q36916140	Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
Q45056972	IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer
Q46367094	IMPACT and AIDIT: Strengthening Research Ties in Eastern Europe
Q35102646	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
Q37006170	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Q29417155	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Q90643254	Identification of Familial Hodgkin Lymphoma Predisposing Genes Using Whole Genome Sequencing
Q36859142	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
Q36086247	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
Q36014067	Identification of novel genetic markers of breast cancer survival
Q46738244	Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
Q47909607	Identification of patients at high risk of psychological distress after BRCA1 genetic testing
Q35541663	Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Q46103372	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Q34467646	Immunophenotypic predictive profiling of BRCA1-associated breast cancer
Q55717426	Impact of BRCA1 mutation on survival after early onset breast cancer.
Q33633402	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation
Q35914749	Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool
Q37507426	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
Q114184688	Incorporating progesterone receptor expression into the PREDICT breast prognostic model
Q48229822	Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype
Q46491247	Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation
Q61946730	Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation
Q46569831	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study
Q33330464	Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk
Q81425159	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland
Q114727447	Influence of the Levels of Arsenic, Cadmium, Mercury and Lead on Overall Survival in Lung Cancer
Q92821442	Influence of the selenium level on overall survival in lung cancer
Q37410472	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women
Q90776681	Inherited NBN Mutations and Prostate Cancer Risk and Survival
Q90723593	Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer
Q37684424	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration
Q92972068	Inherited variants in XRCC2 and the risk of breast cancer
Q35104068	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
Q40448761	Inhibition of cell cycle and induction of apoptosis by sulforaphane in cell lines carrying various inherited BRCA1 mutations.
Q84035369	Iniparib in metastatic triple-negative breast cancer
Q91056732	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Q92554734	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Q90207660	Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes
Q42550934	Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk
Q111312503	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia
Q90181459	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Q28394515	International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants
Q36168564	International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers
Q93012417	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
Q34116505	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers
Q34081324	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer
Q30277784	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer
Q47101354	Iron and breast cancer risk
Q46130512	Iron as diagnostic marker of cancer.
Q61818385	Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence
Q83180389	Is there any relationship between BRCA1 gene mutation and pancreatic cancer development?
Q47880750	LDL-R and Apo-B-100 gene mutations in Polish familial hypercholesterolemias
Q61946722	Lack of association between genetic polymorphisms in cytokine genes and disease expression in patients with hereditary non-polyposis colorectal cancer
Q46478736	Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden
Q43437825	Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families
Q33994507	Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome
Q57191573	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair
Q28267893	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Q29416989	Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Q61946736	Long polymerase chain reaction in detection of germline deletions in the von Hippel-Lindau tumour suppressor gene
Q35627411	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
Q56435837	Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
Q94473101	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers
Q73204422	Loss or reduction of Fhit expression in renal neoplasias: correlation with histogenic class
Q61946742	Losses at 3p common deletion sites in subtypes of kidney tumours: histopathological correlations
Q35119701	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
Q81803706	Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland
Q42244979	Low-risk Genes and Multi-organ Cancer Risk in the Polish Population
Q97550039	Lung Cancer Occurrence-Correlation with Serum Chromium Levels and Genotypes
Q24649980	Lung cancer susceptibility locus at 5p15.33
Q37328144	Lynch syndrome (HNPCC).
Q54918514	Lynch syndrome mutations in Poland and the Baltic States.
Q45956204	Lynch syndrome mutations shared by the Baltic States and Poland.
Q61946725	MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk
Q61946723	MDM2 SNP309 T>G alone or in combination with theTP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients
Q42245043	MSH2 and MLH1 testing
Q22001356	MSH6 syndrome
Q34326141	MTHFR 677 C>T and 1298 A>C polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer
Q46130429	Magnesium as a diagnostic marker of cancer.
Q31043651	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Q51830222	Male to female ratio among offspring of BRCA1 mutation carriers.
Q59238246	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study
Q34988799	Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families
Q111660895	Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Q47133182	Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015.
Q50233852	Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016.
Q92860654	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers
Q114182490	Mendelian randomisation study of smoking exposure in relation to breast cancer risk
Q85921942	Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer
Q79298327	Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks
Q44542942	MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer
Q34497352	MicroRNA related polymorphisms and breast cancer risk
Q46130604	Microelements as diagnostic markers of pancreatic cancer.
Q55646266	Microelements as risk factors for cancer of the lung and larynx.
Q46098026	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland
Q56994400	Mitochondrial genotype and breast cancer predisposition
Q83180766	Modest association of malignant melanoma with the rs910873 and rs1885120 markers on chromosome 20: a population-based study
Q34992182	Molecular basis of inherited predispositions for tumors.
Q35676798	Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations
Q73204828	Molecular evidence for derivation of metastatic cells from minor subclones of primary clear renal cell carcinomas
Q68020076	Molecular genetic analysis in the diagnosis of lymphoma in fine needle aspiration biopsies. I. Lymphomas versus benign lymphoproliferative disorders
Q68020079	Molecular genetic analysis in the diagnosis of lymphoma in fine needle aspiration biopsies. II. Lymphomas versus nonlymphoid malignant tumors
Q36897003	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Q61945797	Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography
Q57377904	Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma
Q91503301	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype
Q49024646	Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations.
Q55001307	Mutations and polymorphisms of genes moderate increase in gastric cancer risk.
Q98896840	Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland
Q38449441	Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas
Q54314566	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Q55403547	Mutations spectrum in hereditary disorders predisposing to occurrence of intestine polyposis in Poland.
Q52675313	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Q59288487	NBS1 Mutation and prognosis of prostate cancer
Q51029363	NBS1 is a prostate cancer susceptibility gene.
Q61946727	NOD2 variants and the risk of malignant melanoma
Q46250020	Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Q59255480	Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Q26799669	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk
Q61946712	New EPCAM founder deletion in Polish population
Q30275832	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Q30374367	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Q37079859	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing
Q38481733	Non-isotopic procedure with silver staining of polyacrylamide gels in detection of genomic abnormalities in tumors using microsatellites
Q43073995	Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland
Q33879464	Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study
Q74826554	Novel RB1 gene constitutional mutations found in Polish patients with familial and/or bilateral retinoblastoma
Q35559901	Novel germline mutations in the adenomatous polyposis coli gene in Polish families with familial adenomatous polyposis
Q28139857	Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families
Q39581968	Nuclear Pedigree Criteria for the Identification of Individuals Suspected to be at Risk of an Inherited Predisposition to Renal Cancer
Q55380004	Nuclear Pedigree Criteria of Suspected HNPCC.
Q39659021	Nuclear pedigree criteria for the identification of individuals suspected to be at risk of an inherited predisposition to gastric cancer
Q46538007	Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study
Q34705352	On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations
Q36671223	Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q91524809	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers
Q31804977	Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes
Q37524764	Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
Q34162534	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q61946731	Ovarian cancer of endometrioid type as part of the MSH6 gene mutation phenotype
Q33327308	Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
Q36280191	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Q54308947	Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Q78300447	Overexpression of cyclin E protein is closely related to the mutator phenotype of colorectal carcinoma
Q114677296	PALB2 mutations and prostate cancer risk and survival
Q28584533	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Q39575484	PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
Q35755860	PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPEL-LINDAU EYE DISEASE.
Q47143943	PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1.
Q43222794	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy
Q38240441	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
Q36132338	Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers
Q46130542	Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Q112572520	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes
Q81601356	Pathology of breast cancer in women with constitutional CHEK2 mutations
Q37307937	Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium
Q28386134	Pedigree based DNA sequencing pipeline for germline genomes of cancer families
Q83145997	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Q43232347	Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling
Q50194011	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Q39553159	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study
Q60585018	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study
Q51672667	Pleomorphic adenoma of salivary glands does not appear to be a BRCA-1-dependent tumour in a Polish cohort.
Q39712677	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Q62583133	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Q97524107	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Q85215516	Polymorphic variants in VAX1 gene (rs7078160) and BMP4 gene (rs762642) and the risk of non-syndromic orofacial clefts in the Polish population
Q53855921	Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients.
Q61946738	Polymorphism of GSTM1 gene in patients with colorectal cancer and colonic polyps
Q98240553	Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population
Q36066735	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Q35089115	Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population
Q42244986	Population Screening of CHEK2 Mutations in Poland
Q42244983	Population screening for cancer family syndromes in the west pomeranian region of poland
Q96431220	Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
Q61945682	Possible association of the BRCA2 gene C5972T variant with gastric cancer: a study on Polish population
Q98951238	Pre-Pregnancy Obesity vs. Other Risk Factors in Probability Models of Preeclampsia and Gestational Hypertension
Q92055460	Prediction and clinical utility of a contralateral breast cancer risk model
Q36583004	Prediction of breast cancer risk based on profiling with common genetic variants
Q91832507	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts
Q41584352	Prediction of individual genetic risk to prostate cancer using a polygenic score
Q46808117	Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group
Q49787762	Predictors of survival for breast cancer patients with a BRCA1 mutation.
Q90979537	Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients
Q44429695	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer
Q35665705	Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
Q98618547	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
Q98952362	Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population
Q51116126	Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.
Q43676019	Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study
Q61946726	Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer
Q37327974	Principles of genetic predisposition to malignancies
Q96027123	Prognostic gene expression signature for high-grade serous ovarian cancer
Q46888326	Prospective clinical trials on correlations between macro-/ microelements and vitamins and cancer risk
Q87232422	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Q95725188	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers
Q46738201	Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
Q59288310	Prostate cancer screening based on genotyping for high risk founder alleles
Q49340500	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Q54944326	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Q104799882	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
Q36985655	Psoriasis vulgaris and familial cancer risk- a population-based study.
Q55508030	Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
Q90242034	Publisher Correction: Shared heritability and functional enrichment across six solid cancers
Q36512097	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
Q36009422	RAD51B in Familial Breast Cancer
Q28943461	Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
Q47841511	Rarity of germline 1100delC mutation in CHK2 in patients with malignant melanoma of the skin
Q79167034	Re: Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease
Q44813939	Recommendations to improve identification of hereditary and familial colorectal cancer in Europe.
Q122937357	Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
Q104801925	Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population
Q45185763	Recurrent mutations of BRCA1 and BRCA2 in Poland: an update
Q36538025	Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
Q35155449	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia
Q91494333	Reply to 'Mutations in RECQL are not associated with breast cancer risk in an Australian population'
Q44884896	Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study
Q57908386	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
Q34579373	Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers
Q81688258	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Q36924418	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Q83164988	Retinal dysfunction in eyes of patients with BRCA1 gene mutation
Q44434245	Retinal function in the von Hippel-Lindau disease
Q37129828	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study
Q40287145	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
Q51421155	Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Q37624504	Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10
Q48251790	Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility.
Q55042194	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Q53256330	Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
Q59288380	Screening with Magnetic Resonance Imaging in women at low and intermediate risk of breast Cancer
Q37676814	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer
Q64093334	Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
Q59288376	Selenium (Se) and breast cancer risk
Q46250119	Selenium (Se) and the risk of breast, ovarian and prostate cancers
Q59270665	Selenium and cancer risk in CHEK2 mutation carriers
Q46942218	Selenium and gastrointestinal cancers risk
Q59270663	Selenium and risk of bladder cancer
Q50219543	Selenium and the risk of cancer in BRCA1 carriers.
Q46250105	Selenium and the risk of cancer of the lung and larynx. A case-control study from a region with low selenium.
Q46250204	Selenium and the risk of cancers of the colon, pancreas and stomach
Q38359733	Selenium as a marker of cancer risk and of selection for control examinations in surveillance
Q46130885	Selenium as diagnostic marker of cancers.
Q38067529	Selenium as marker for cancer risk and prevention
Q43258112	Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers
Q48273027	Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence
Q37097470	Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer
Q90662745	Serum Microelements in Early Pregnancy and their Risk of Large-for-Gestational Age Birth Weight
Q64997461	Serum Selenium Level in Early Healthy Pregnancy as a Risk Marker of Pregnancy Induced Hypertension.
Q46332902	Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers.
Q59270668	Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
Q54487901	Serum concentrations of Cu, Se, Fe and Zn in patients diagnosed with pancreatic cancer.
Q33664315	Serum folate concentration and the incidence of lung cancer
Q92341152	Serum selenium level and cancer risk: a nested case-control study
Q48303390	Serum selenium levels and the risk of progression of laryngeal cancer
Q91803538	Serum selenium levels are associated with age-related cataract
Q50086084	Serum selenium levels predict survival after breast cancer.
Q29417074	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
Q92969786	Sex specific associations in genome wide association analysis of renal cell carcinoma
Q36089391	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer
Q61118451	Shared heritability and functional enrichment across six solid cancers
Q64004349	Shared heritability and functional enrichment across six solid cancers
Q37330520	Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions
Q44732177	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Q59238433	Smoking and the risk of breast cancer among carriers of BRCA mutations
Q34548726	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update
Q34037953	Smoking related cancers and loci at chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish population
Q36091723	Sonographic imaging of Spigelian hernias
Q35012736	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
Q40510914	Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NAD(P)H:quinone reductase and apoptosis in human lymphoblastoid cells.
Q33732342	Supernormal electro-oculograms in patients with neurofibromatosis type 1.
Q54375866	Survival from breast cancer in patients with CHEK2 mutations.
Q77907349	Survival in patients with rare subtypes of renal cell carcinoma
Q53670145	Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study.
Q43425193	Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk
Q46838391	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update
Q37129654	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
Q33927384	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Q46935108	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
Q44251009	Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer
Q46347968	Thank you to all our manuscript reviewers in 2014.
Q54467282	Thank you to all our manuscript reviewers in 2015.
Q35203356	The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract
Q44306036	The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation
Q47127499	The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population
Q33722537	The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs
Q45140865	The 3020insC NOD2 gene mutation in patients with ovarian cancer.
Q45114407	The 3020insC allele of NOD2 predisposes to early-onset breast cancer
Q54503913	The 4154delA mutation carriers in the BRCA1 gene share a common ancestry.
Q122923741	The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
Q61945695	The Association Between the Interleukin-1 Polymorphisms and Gastric Cancer Risk Depends on the Family History of Gastric Carcinoma in the Study Population
Q33722515	The Association of the COMT V158M Polymorphism with Endometrial/Ovarian Cancer in HNPCC Families Adhering to the Amsterdam Criteria
Q36615665	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
Q45973022	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
Q49817640	The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity.
Q46738190	The CHEK 2 GENE mutations and the risk of Gastric cancer
Q33675997	The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q40776729	The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation
Q91178389	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Q44733776	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland
Q36438352	The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer
Q99571015	The Influence of Maternal BMI on Adverse Pregnancy Outcomes in Older Women
Q34800968	The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers
Q37329303	The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?
Q48010156	The NOD2 3020insC mutation and the risk of colorectal cancer
Q33584095	The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
Q79776026	The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers
Q47563569	The Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers without a First-Degree Relative with Breast Cancer
Q90334432	The Role of Early Pregnancy Maternal Selenium Levels on the Risk for Small-for-Gestational Age Newborns
Q80436355	The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women
Q47560912	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers
Q44326522	The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania
Q54426242	The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Q34333988	The effect on melanoma risk of genes previously associated with telomere length
Q38809495	The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania
Q38777240	The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients
Q113675313	The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations
Q37613551	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation
Q53112682	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Q36898423	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
Q36451732	The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
Q60921979	The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study
Q53849040	The influence of selenium concentration and variations in selenoprotein genes on the CHEK2-dependent cancers.
Q93085465	The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer
Q42368096	The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
Q40137412	The presence of prostate cancer at biopsy is predicted by a number of genetic variants
Q44628695	The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study
Q35907001	The risk of breast cancer in women with a BRCA1 mutation from North America and Poland
Q46738314	The risk of breast cancer in women with a CHEK2 mutation
Q53250018	The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
Q45259012	The risk of gastric cancer in carriers of CHEK2 mutations
Q53304250	The rs1447295 and DG8S737 markers on chromosome 8q24 and cancer risk in the Polish population.
Q92585127	The spectrum of mutations predisposing to familial breast cancer in Poland
Q61952806	The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men
Q61946719	The −149C>T SNP within the ΔDNMT3B gene, is not associated with early disease onset in hereditary non-polyposis colorectal cancer
Q44256039	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers
Q114677146	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Q89961489	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Q62588939	Translocation (X;1)(p11.2;q21) in a papillary renal cell carcinoma in a 14-year-old girl.
Q68493747	Transmission electron microscopy in the diagnosis of metastases of malignant melanoma using specimens obtained by fine-needle puncture biopsy
Q68493751	Transmission electron microscopy in the differential diagnosis of thyroid tumors using specimens obtained by fine-needle puncture biopsy
Q43073174	Transmission of mutant alleles to female offspring of BRCA1 carriers in Poland
Q46801017	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
Q92994868	Two truncating variants in FANCC and breast cancer risk
Q42691689	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing
Q55036759	Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers.
Q30588580	Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer
Q33654709	Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility
Q56342454	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility
Q33847791	Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer
Q46512471	Vitamin D receptor variants and breast cancer risk in the Polish population
Q84398671	Vitamin D receptor variants and the malignant melanoma risk: a population-based study
Q40641271	Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation
Q46738293	Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Q52570748	XPD common variants and their association with melanoma and breast cancer risk.
Q34597801	Xeroderma pigmentosum genes and melanoma risk
Q46660029	Zinc and breast cancer risk
Q45946070	Zinc as diagnostic marker of cancers.
Q69789157	[A rapid method of preparing specimens obtained by fine-needle biopsy for transmission electron microscopy]
Q72930982	[Behavior of SCC antigen in girls with a high risk of developing cervical carcinoma]
Q70475999	[Detection of tumor virus infections with HPV 16, 18, and 33 from cytologic material in the uterine neck using the PCR method]
Q71953220	[Diagnosis of Mycobacterium tuberculosis infections using PCR methods]
Q69812726	[Differential diagnosis of cancer by fine-needle aspirates using transmission electron microscopy. III. Undifferentiated cancer (anaplastic)]
Q68972294	[Differential diagnosis of cancer in fine needle aspirates using transmission electron microscopy. I. Adenocarcinoma]
Q36466889	[Differential diagnosis of cancer in fine-needle biopsy aspirates using the transmission electron microscope. II. Squamous cell carcinoma]
Q83155116	[HLA-G alleles and risk of early pregnancy loss]
Q70475996	[HPV virus infections and other promotion factors of the carcinogenic process in girls]
Q77055354	[Hereditary ovarian cancer: summary of 5 years of experience]
Q72667667	[RFLP-PCR technique for exclusion of carrier status of the mutated Rb gene]
Q69760959	[Transmission electron microscopy in the differential diagnosis of malignant neoplasms using fine-needle aspirates]
Q69836161	[Transmission electron microscopy in the differential diagnosis of malignant small round cell tumors of childhood using biopsy aspirates]
Q68069967	[Transmission electron microscopy in the differential diagnosis of non-Hodgkin's lymphoma using fine-needle aspirates]
Q69854139	[Transmission electron microscopy in the differential diagnosis of soft tissue and bone sarcomas and germinal tumors using fine needle aspirates]
Q72648344	[VNTR-PCR in diagnosis of inherited Rb gene mutation]
Q122925830	p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Q37414133	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk
Q56334023	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

P2671	Google Knowledge Graph ID	/g/12111_8k
P213	ISNI	000000011318015X
P1207	NUKAT ID	n99001769
P496	ORCID iD	0000-0003-2931-3003
P7293	PLWABN ID	9810583656805606
P3124	Polish scientist ID (deprecated)	73047
P1153	Scopus author ID	7005557039
P214	VIAF ID	165205872
P7859	WorldCat Identities ID (superseded)	viaf-165205872

P512	academic degree	scientific professorship degree	Q55695329
P166	award received	Officer of the Order of Polonia Restituta	Q15715251
P27	country of citizenship	Poland	Q36
P1889	different from	John I of Lüben	Q442595
P185	doctoral student	Elżbieta Złowocka-Perłowska	Q38305600
		Cezary Cybulski	Q42590472
		Joanna Trubicka	Q56839941
		Anna Jakubowska	Q58323317
		Marcin Lener	Q92201896
		Tomasz Huzarski	Q97187823
		Janina Suchy	Q114456208
		Malgorzata Stawicka-Nielacna	Q114456213
		Katarzyna Nej-Wołosiak	Q114456237
		Karol Krzystolik	Q114456312
		Tomasz Byrski	Q58345332
		Pawel Domagala	Q61946841
		Piotr Hadaczek	Q67212166
		Konrad Ptaszyński	Q71047364
		Jolanta Szymanska-Pasternak	Q79862095
		Małgorzata Chruściel-Nogalska	Q86492195
		Wojciech Marciniak	Q90774458
		Jacek Gronwald	Q91084015
		Tadeusz Dębniak	Q92032189
P108	employer	Pomeranian Medical University	Q694887
P734	family name	Lubiński	Q27941977
		Lubiński	Q27941977
		Lubiński	Q27941977
P101	field of work	oncology	Q162555
		clinical genetics	Q5877314
P735	given name	Jan	Q12173670
		Jan	Q12173670
		Antoni	Q17480899
		Antoni	Q17480899
P1412	languages spoken, written or signed	Polish	Q809
P1559	name in native language	Jan Lubiński
P106	occupation	researcher	Q1650915
		pathologist	Q3368718
		oncologist	Q16062369
P21	sex or gender	male	Q6581097

Q58323317	Anna Jakubowska
Q42590472	Cezary Cybulski
Q38305600	Elżbieta Złowocka-Perłowska
Q91084015	Jacek Gronwald
Q114456208	Janina Suchy
Q56839941	Joanna Trubicka
Q79862095	Jolanta Szymanska-Pasternak
Q114456312	Karol Krzystolik
Q114456237	Katarzyna Nej-Wołosiak
Q71047364	Konrad Ptaszyński
Q114456213	Malgorzata Stawicka-Nielacna
Q92201896	Marcin Lener
Q86492195	Małgorzata Chruściel-Nogalska
Q61946841	Pawel Domagala
Q67212166	Piotr Hadaczek
Q92032189	Tadeusz Dębniak
Q58345332	Tomasz Byrski
Q97187823	Tomasz Huzarski
Q90774458	Wojciech Marciniak

	Category:Jan Lubiński	wikimedia
	Jan Lubiński	wikipedia

Jan Lubiński

Polish oncologist, pathologist and hereditary cancer researcher

Reverse relations

The articles in Wikimedia projects and languages